The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

The study, published Friday during the 32nd European Congress on Obesity in Spain, also found these GLP-1 drugs were more effective than a drug called ... in alcohol use to explore a possible ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Weight Loss Drug Users Are Giving Up Their Vices This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers ... The Acosta Group study confirms the growing interest in GLP-1 products and shows how this therapeutic option has ...

The real-world study involved ... by nalmefene, a drug used to treat alcohol use disorder in Europe, notes Professor le Roux. He adds: “The exact mechanism of how GLP-1 analogues reduce alcohol ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...

In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive ... doses and longer duration of use. Additionally, body mass index (BMI), which shows body weight adjusted for height ...